Prostate Cancer Patients Just Gained a New Radioligand Option, but Only Licensed Centers Can Give It
FDA expanded Pluvicto to hormone-sensitive metastatic prostate cancer, nearly doubling eligibility. Only licensed nuclear medicine centers can administer it.
Medical Daily ·